In addition, FGL1 has been found to be involved in obesity, lung fibrosis, preeclampsia, diabetes mellitus, non-alcoholic fatty liver disease, and hyperlipidemia (Wu et al., 2013; Li et al., 2016; Jin et al., 2019; Kang et al., 2020; Wu et al., 2020; Cheng et al., 2021). Here, FGL1 is linked to metabolic dysfunction-associated steatotic liver disease.